Brussels, 22/12/2005 (Agence Europe) - The management board of the European Agency for the Evaluation of Medicinal Products (EMEA) adopted the work programme for 2006 on 15 December. The programme will essentially depend on entry into force of the revised European pharmaceutical legislation which extends the centralised procedure for marketing authorisation (AMM) of medicines to all new active principles. The agency therefore expects there will be a rise in requests for approval, from 40 in...